Phenotypes associated with this allele

• Allele Symbol: Spi1^tm2.1Dgt
• Allele Name: targeted mutation 2.1, Daniel G Tenen
• Allele ID: MGI:3688440
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Spi1^tm2.1Dgt/Spi1^tm2.1Dgt	B6.Cg-Spi1^tm2.1Dgt	MGI:3688719
cn2	Spi1^tm2.1Dgt/Spi1^tm2Dgt Tg(Mx1-cre)1Cgn/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:3688720
cn3	Runx1^tm3Spe/Runx1^tm3Spe Spi1^tm2.1Dgt/Spi1^tm2.1Dgt Tg(Mx1-cre)1Cgn/0	involves: 129S4/SvJae * C57BL/6 * CBA	MGI:3793733

Genotype
MGI:3688719

hm1

• Allelic Composition: Spi1^tm2.1Dgt/Spi1^tm2.1Dgt
• Genetic Background: B6.Cg-Spi1^tm2.1Dgt

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

prenatal lethality, complete penetrance ( J:114150 )

• no viable homozygous pups are recovered at birth

hematopoietic system

abnormal blood cell morphology/development ( J:114150 )

• common myeloid progenitors (CMPs) and granulocyte/macrophaged progenitors (GMPs) are undetectable in fetal liver at E14.5 while megakaryocyte/erythrocyte progenitors (MEPs) are relatively increased

decreased hematopoietic stem cell number ( J:114150 )

• number of fetal hematopoietic stem cells (HSCs) in fetal liver is reduced 10-fold compared with wild-type at E14.5

abnormal hematopoietic system physiology ( J:114150 )

• fetal liver cells can home to the bone marrow when transplanted into lethally-irradiated hosts, but cannot maintain HSC pool or contribute to myelopoiesis or lymphopoiesis

Genotype
MGI:3688720

cn2

• Allelic Composition: Spi1^tm2.1Dgt/Spi1^tm2Dgt; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

hematopoietic system

abnormal blood cell morphology/development ( J:114150 )

• 2-3 weeks after induction of cre expression with pI-pC, number of HSCs in bone marrow is decreased with loss of CMPs, GMPs and mature myeloid cells while MEPs are increased; mature granulocytes have disappeared

Genotype
MGI:3793733

cn3

• Allelic Composition: Runx1^tm3Spe/Runx1^tm3Spe; Spi1^tm2.1Dgt/Spi1^tm2.1Dgt; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * CBA

immune system

decreased thymus weight ( J:131217 )

• after pIpC treatment, thymus weight is less than in wild-type mice but greater than in Runx1^tm3Spe/Runx1^tm3Spe Tg(Mx1-cre)1Cgn mice

increased spleen weight ( J:131217 )

• after pIpC treatment

increased granulocyte number ( J:131217 )

• after pIpC treatment, the number of Gr-1+Mac1+ cells in the spleen is increased 8-fold compared to in wild-type mice

decreased B cell number ( J:131217 )

• after pIpC treatment, the B cell compartment is reduced in the spleen and bone marrow

hematopoietic system

decreased thymus weight ( J:131217 )

• after pIpC treatment, thymus weight is less than in wild-type mice but greater than in Runx1^tm3Spe/Runx1^tm3Spe Tg(Mx1-cre)1Cgn mice

increased spleen weight ( J:131217 )

• after pIpC treatment

increased granulocyte number ( J:131217 )

• after pIpC treatment, the number of Gr-1+Mac1+ cells in the spleen is increased 8-fold compared to in wild-type mice

decreased B cell number ( J:131217 )

• after pIpC treatment, the B cell compartment is reduced in the spleen and bone marrow

endocrine/exocrine glands

decreased thymus weight ( J:131217 )

• after pIpC treatment, thymus weight is less than in wild-type mice but greater than in Runx1^tm3Spe/Runx1^tm3Spe Tg(Mx1-cre)1Cgn mice

growth/size/body

increased spleen weight ( J:131217 )

• after pIpC treatment